An Abbvie Inc. patent has disclosed thiazolo [5,4-b] pyridine compounds acting as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL).